User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6436

Interactions with Platform & by Email *

INTERACTIONS

1030

Unique # Participated *

PARTICIPANTS

193

Responses Validated *

VALIDATIONS

42

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Multikinase Inhibitors.....I-3
  
   Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other
  emerging drug classes.).....I-4
  
   Kidney Cancer – Factsheet.....II-11$100
   Market Scenario.....II-2
Multikinase Inhibitors Dominate the Market.....II-2
1$100
   Presently Approved Drugs for the Treatment of Advanced Renal Cell Carcinoma
  (RCC).....II-3
Kidney Cancer Bodes Significant Potential for Targeted Therapies.....II-3
1$100
   Leading Kidney Cancer Drugs.....II-4
Pfizer’s Sutent Tops the RCC Drugs Market.....II-4
Table 1: Leading Kidney Cancer Drugs Worldwide (2009): Sales for Sutent, Nexavar, Afinitor, Avastin, and Proleukin.....II-4
GSK’s Votrient Threatens Sutent’s Dominance.....II-4
1$350
   Nexavar Dominates Second Line Treatment for RCC.....II-5 1$100
   Table 2: Leading Drugs in the Second Line Treatment of RCC (2011): Market Share Breakdown for Nexavar, Torisel, Afinitor, Avastin, and Others (includes corresponding Graph/Chart).....II-6
Torisel Leads Third Line Treatment for RCC.....II-6
Table 3: Leading Drugs in the Third Line Treatment of RCC (2017E): Market Share Breakdown for Afinitor, Axitinib, Avastin, Torisel, and Others (includes corresponding Graph/Chart).....II-6
1$350
   Kidney Cancer: Disease Overview.....II-7
Causes.....II-7
Symptoms and Signs.....II-7
Stages.....II-7
1$100
   Renal Cell Carcinoma (RCC): The Most Common Kidney Cancer.....II-8
Types.....II-8
Symptoms and Signs.....II-8
Diagnosis.....II-8
1$100
   Surgical Treatment.....II-91$100
   Targeted Therapies.....II-10
Multi-kinase Inhibitors.....II-10
mTOR Inhibitors.....II-10
1$100
   Oral Targeted Therapies.....II-11
Injectable Targeted Therapy.....II-11
Pros and Cons of Targeted Therapies.....II-11
Monoclonal Antibodies.....II-11
Immunomodulators.....II-11
1$100
   Aldesleukin (Proleukin®).....II-12
Interferon alpha-2 (Roferon-A®).....II-12
1$100
   Sutent (Sunitinib).....II-13
Sutent Vs. Interferon-alpha and IFN-alpha therapies.....II-13
Nexavar (Sorafenib).....II-13
1$100
   Torisel (Temsirolimus).....II-14
Votrient (Pazopanib).....II-14
Avastin (Bevacizumab).....II-14
Afinitor (Everolimus).....II-14
1$100
   Select Kidney Cancer Pipeline: As of 2010.....II-15
Select Pipeline Drugs – A Review.....II-15
Axitinib (Pfizer).....II-15
Tivozanib (AVEO Pharmaceuticals).....II-15
1$100
   RENCAREX (WILEX).....II-16
TroVax (Oxford BioMedica).....II-16
1$100
   Cancer Incidence – Statistics on New Cases.....II-17
Table 4: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart).....II-17

Table 5: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart).....II-17
1$350
   Table 6: Cancer Incidence in Upper Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-181$350
   Table 7: Cancer Incidence in Lower Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-191$350
   Table 8: Cancer Incidence in High Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-201$350
   WILEX Grants Exclusive US Commercialisation Rights for RENCAREX to Prometheus.....II-21
AVEO Collaborates with Astellas to Develop and Commercialize Tivozanib.....II-21
Novartis Sells Proleukin US Rights to Prometheus Laboratories.....II-21
1$100
   WILEX Announces End Results of REDECT Phase 3 Registration Trial with
  Redectane®.....II-22
NICE Rejects Novartis’ Kidney Cancer Drug Everolimus.....II-22
GlaxoSmithKline Gains Conditional EU Approval for Votrient (pazopanib).....II-22
Prometheus and Novartis Enters into Commercialization Agreement.....II-22
Cipla Launches Soranib Cancer Medicine.....II-22
1$100
   Bristol-Myers Squibb Divests Nutrition Business, Mead Johnson Nutrition, to Focus on
  Biopharma Business.....II-23
Roche Acquires Genentech.....II-23
Novartis’ Afinitor® Obtains EC Approval for Advanced RCC Treatment.....II-23
Novartis Obtains FDA Approval for Afinitor.....II-23
Roche Receives FDA Approval for Avastin in Combination with Interferon-Alpha for RCC
  Treatment.....II-23
1$100
   Pfizer’s Sutent Obtains Recommendation as First Line Treatment for mRCC.....II-24
GlaxoSmithKline Receives FDA Approval for Votrient.....II-24
1$100
   Oxford BioMedica’s TroVax Fails Kidney Cancer Clinical Trial.....II-25
Genomic Health to Collaborate with Pfizer for New Genomic Test.....II-25
Roche’s Avastin Bags European Approval for Renal Cancer Treatment.....II-25
Wyeth’s TORISEL Receives FDA Approval.....II-25
AstraZeneca’s Novel Cancer Drug, AZD2171, Dubbed Recentin.....II-25
1$100
   AVEO Pharmaceuticals (US).....II-26
Bayer AG (Germany).....II-26
1$100
   Bristol-Myers Squibb Co. (US).....II-27
Onyx Pharmaceuticals, Inc. (US).....II-27
F. Hoffmann-La Roche Ltd. (Switzerland).....II-27
1$100
   GlaxoSmithKline Plc. (UK).....II-28
Merck-Serono (Switzerland).....II-28
1$100
   Novartis AG (Switzerland).....II-29
Pfizer, Inc. (US).....II-29
WILEX AG (Germany).....II-29
2$125
   Table 9: World Recent Past, Current & Future Analysis for Renal Cell Carcinoma (RCC) Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-311$350
   Table 10: World 10-Year Perspective for Renal Cell Carcinoma (RCC) Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....II-321$350
   Table 11: World Recent Past, Current & Future Analysis for Multikinase Inhibitors by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-331$350
   Table 12: World 10-Year Perspective for Multikinase Inhibitors by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....II-341$350
   Table 13: World Recent Past, Current & Future Analysis for Other RCC Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-351$350
   Table 14: World 10-Year Perspective for Other RCC Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....II-361$350
   A. Market Analysis.....III-1
Cancer Statistics in the US.....III-1
Cancer Incidence Statistics.....III-1
Table 15: New Cancer Cases in the US by Affected Site: 2009.....III-1
2$200
   Table 16: New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....III-31$200
   Table 17: New Cancer Cases in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart).....III-4
Cancer Mortality Statistics.....III-4
Table 18: Cancer Related Deaths in the US by Affected Site: 2009.....III-4
2$200
   Table 19: Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....III-61$200
   Table 20: Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart).....III-7
Kidney Cancer Incidence Rates and Mortality Statistics.....III-7
Table 21: Kidney Cancer Incidence Rates by Race/Ethnicity per 10,000 Men (includes corresponding Graph/Chart).....III-7
1$200
   Table 22: Kidney Cancer Incidence Rates by Race/Ethnicity Per 10,000 Women (includes corresponding Graph/Chart).....III-8

Table 23: Kidney Cancer Mortality Rates by Race/Ethnicity per 10,000 Men (includes corresponding Graph/Chart).....III-8
1$200
   Table 24: Kidney Cancer Mortality Rates by Race/Ethnicity Per 10,000 Women (includes corresponding Graph/Chart).....III-9
NCI Funding for Kidney Cancer on the Rise.....III-9
Table 25: NCI’s Annual Funding on Kidney Cancer Research for Years 2007, 2008 & 2009 (includes corresponding Graph/Chart).....III-9
1$200
   Table 26: Allocation of Funds by Scientific/ Research Area (2009) (includes corresponding Graph/Chart).....III-10
Strategic Corporate Developments.....III-10
3$200
   Focus on Select Major Players.....III-132$100
   B. Market Analytics.....III-15
Table 27: The US Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-15
1$200
   Table 28: The US 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-161$200
   A. Market Analysis.....III-17
Cancer Incidence and Mortality Statistics in Canada.....III-17
Table 29: New Cancer Cases by Type/Site Among Canadian Men (2010) (includes corresponding Graph/Chart).....III-17
1$200
   Table 30: New Cancer Cases by Type/Site Among Canadian Women (2010) (includes corresponding Graph/Chart).....III-18

Table 31: Cancer Deaths by Type/Site Among Canadian Men (2010) (includes corresponding Graph/Chart).....III-18
1$200
   Table 32: Cancer Deaths by Type/Site Among Canadian Women (2010) (includes corresponding Graph/Chart).....III-191$200
   B. Market Analytics.....III-20
Table 33: Canadian Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-20
1$200
   Table 34: Canadian 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-211$200
   Market Analytics.....III-22
Table 35: Japanese Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-22
1$200
   Table 36: Japanese 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-231$200
   A. Market Analysis.....III-24
Cancer Statistics in Europe.....III-24
Table 37: Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart).....III-24
1$200
   Strategic Corporate Developments.....III-251$75
   B. Market Analytics.....III-26
Table 38: European Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of European Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-26
1$200
   Table 39: European 10-Year Perspective for Renal Cell Carcinoma Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of European Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-271$200
   Table 40: European Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-281$200
   Table 41: European 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-291$200
   Market Analytics.....III-30
Table 42: French Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-30
1$200
   Table 43: French 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-311$200
   A. Market Analysis.....III-32
Strategic Corporate Development.....III-32
Focus on Select Major Players.....III-32
2$100
   B. Market Analytics.....III-34
Table 44: German Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-34
1$200
   Table 45: German 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-351$200
   Market Analytics.....III-36
Table 46: Italian Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-36
1$200
   Table 47: Italian 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-371$200
   A. Market Analysis.....III-38
Kidney Cancer Statistics.....III-38
Strategic Corporate Developments.....III-38
1$75
   Focus on Select Major Players.....III-391$75
   B. Market Analytics.....III-40
Table 48: The UK Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-40
1$200
   Table 49: The UK 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-411$200
   A. Market Analysis.....III-42
Focus on Select Major Players.....III-42
1$75
   B. Market Analytics.....III-43
Table 50: Rest of European Recent Past, Current & Future Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-43
1$200
   Table 51: Rest of European 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-441$200
   A. Market Analysis.....III-45
Cancer Statistics in Asia-Pacific.....III-45
Table 52: Cancer Incidence in Asia-Oceania by Site: 2009 (includes corresponding Graph/Chart).....III-45
1$200
   Product Launch.....III-46
B. Market Analytics.....III-46
Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-46
1$200
   Table 54: Asia-Pacific 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-471$200
   Market Analytics.....III-48
Table 55: Rest of World Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....III-48
1$200
   Table 56: Rest of World 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart).....III-491$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com